Clinical Trial News & Results
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Zepbound (tirzepatide) Showed Superior Weight Loss Over Wegovy (semaglutide) in Complete SURMOUNT-5 Results Published in The New England Journal of Medicine
INDIANAPOLIS, May 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical...
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial of Efruxifermin in the New England Journal of Medicine
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...
Icotrokinra Results Show Significant Skin Clearance in Patients with Difficult-to-Treat Scalp and Genital Psoriasis
SPRING HOUSE, Pa. (May 9, 2025) – Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating...
GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus in Primary Biliary Cholangitis
London, UK 08 May 2025 -- GSK plc (LSE/NYSE: GSK) today announced positive results from the GLISTEN phase III trial evaluating linerixibat, an investigational...
Boehringer Ingelheim Starts Phase II Study of BI 1584862, Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy
Ingelheim, Germany, May 6, 2025 -- Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy...
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
LEXINGTON, Mass.--(BUSINESS WIRE)--May 5, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and...
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 5 May 2025 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
FDA Accepts Filing Application for Oral Semaglutide 25 mg, Which If Approved, Would Be The First Oral GLP-1 Treatment for Obesity
PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application...
HHS, NIH Launch Next-Generation Universal Vaccine Platform for Pandemic-Prone Viruses
May 1, 2025 -- The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the development of the...
ESSENCE Phase 3 Trial of Semaglutide Showed Significant Improvements at 72 Weeks in Adults with MASH, Published in NEJM
PLAINSBORO, N.J., April 30, 2025 /PRNewswire/ -- Today, The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE...
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-Cell Lymphoma
Lund, Sweden – April 29, 2025 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the...
Boehringer’s New Zongertinib Data Demonstrates Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-Mutant Advanced NSCLC
Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 - Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating...
Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC
LAS VEGAS, April 26, 2025 – Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating...
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK--(BUSINESS WIRE) April 26, 2025 -- Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an...
Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Highest Complete Response Rate with Sustained Clinical Benefits in Patients with Certain Types of Bladder Cancer
LAS VEGAS, April 26, 2025 – Johnson & Johnson (NYSE: JNJ) today announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating...
NIH Study Reveals How Inflammation Makes Touch Painful
April 23, 2025 -- Researchers at the National Institutes of Health (NIH) have discovered clues as to how our bodies turn sensations such as heat and touch into...
Sebela Pharmaceuticals Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD
BRAINTREE, Mass., April 23, 2025 /PRNewswire/ – Braintree Laboratories, a part of Sebela Pharmaceuticals® and a leading manufacturer of...
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
PRINCETON, N.J.--(BUSINESS WIRE) Apr 22, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 ARISE trial evaluating the...
Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial
INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the...
BlueRock Therapeutics Announces Publication in Nature of 18-Month Data from Phase 1 Clinical Trial for Bemdaneprocel, an Investigational Cell Therapy for Parkinson’s Disease
Cambridge MA, USA, April 16, 2025 – BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today...
Clinical trial results archive
- 2025
- January, February, March, April, May
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.